Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311979 | 0.78 | TAAR1 (0.67) | TAAR1MAOBCYP1A2CYP2A6HTR2A | |
| SCHEMBL1713166 | 0.77 | ADRB2 (0.37) | — | |
| SCHEMBL26189798 | 0.77 | TAAR1 (0.61) | TAAR1MAOBCYP1A2CYP2A6HTR2A | |
| SCHEMBL12967309 | 0.76 | L3MBTL1 (0.42) | CYP1A2 | |
| Hydrochloric Acid SCHEMBL1713704 | 0.74 | TAAR1 (0.41) | TAAR1MAOB | |
| SCHEMBL12788471 | 0.73 | TAAR1 (0.75) | TAAR1MAOBCYP1A2CYP2A6 | |
| SCHEMBL1049649 | 0.73 | ALDH1A1 (0.64) | TAAR1MAOB | |
| SCHEMBL1713688 | 0.72 | KDM4E (0.50) | CYP2A6 | |
| SCHEMBL1027713 | 0.71 | TAAR1 (0.63) | TAAR1MAOBCYP1A2CYP2A6 | |
| SCHEMBL28527968 | 0.71 | HTR2A (0.62) | TAAR1CYP2A6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232101-A1 | Novel Compounds | CHAPMAN DAVID (SE) | 2012-09-13 | — | — | US | disclosed |
| US-8183251-B2 | 1-[(4S)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]-N-methyl-N-{[4-(pyrimidin-5-yloxy)phenyl]methyl}methanesulfonamide; matrix metalloproteinase inhibitors; obstructive airways disease is asthma or chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2012-05-22 | — | — | US | disclosed |
| EP-2097406-B1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| US-20080221139-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221139-A1 | Novel Compounds | MMP9, MMP2, MMP1 | TAAR1 3478/4885MAOB 219/4885CYP1A2 96/4885 |
| US-20120232101-A1 | Novel Compounds | MMP9, MMP2, MMP1 | TAAR1 3478/4885MAOB 219/4885CYP1A2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.